Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Telavancin (vibativ), a new option for the treatment of gram-positive infectionsTelavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults.Telavancin: a review of its use in patients with nosocomial pneumonia.Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureusVancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Successful target attainment of telavancin at elevated MICs: fact or fiction?Pharmacokinetics of Telavancin at Fixed Doses in Normal Body Weight and Obese (Classes I, II, and III) Adult Subjects.Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
P2860
Q26771850-5C08B37B-21F6-44B5-82F4-4FBAEE6904EEQ34677611-AE6132D3-4C5D-4173-AAF5-CBAC0D31E9ADQ34906520-1492465C-71EC-421C-8175-24A560C1374BQ35905561-1790630B-D711-4197-B391-8E54F9BB6233Q36439072-FEBEF281-0445-4A35-AC4A-1DEEF16F1493Q38084726-1A7DF5E1-2836-4D43-A9DF-F5B85C85991DQ38159966-AE5BBC60-1257-4A73-BCD8-728C04F22497Q38575714-92076945-A25B-4F87-966C-4ABF95E72EF2Q38829519-B6BE106B-4388-4665-8918-6CF68419DEE1Q40326741-C1744C30-1AF8-42D4-8708-0707A8D7029AQ40804939-E821EAC8-7B86-4B93-995F-873CA45862C4Q41445957-B57F7E4F-3BF4-4621-9848-5A82600E97ECQ42090736-D83FCFEB-8A37-47C1-B40D-12D209E104FDQ42280738-5B3F256F-888C-4BD3-808B-E841A37A8D26Q42530056-DEFD55B5-67A4-45A6-A3B6-2185DD5A039EQ43243482-D4B7A20B-2838-4ED8-999A-0FF7DD6705D0Q47172132-61689506-0DAC-4D60-8DFC-82554F24C7E3Q50053159-F67601E1-9C4E-495E-ACFE-711F22827CCA
P2860
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection
@en
type
label
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection
@en
prefLabel
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection
@en
P2093
P2860
P356
P1476
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection
@en
P2093
Alan R Noel
Alasdair P MacGowan
Heather C Elliott
Karen E Bowker
Sharon Tomaselli
P2860
P304
P356
10.1128/AAC.00933-10
P407
P577
2010-11-15T00:00:00Z